BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Nomura Maintains Buy on Fortis Healthcare
Nomura says that the process of recovery is underway as seen in the improvement in margins. However, Q1FY16 suggests that the pace of recovery is slower than our estimates. The longer-term estimates are not likely to change materially. We retain our buy rating with a DCF-based 12 month target price of Rs 238 share.